Streetbeat News

WGS

GeneDx Holdings Corp.

http://www.genedx.com

Industry

Medical - Healthcare Information Services

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Open

66.36

Mkt cap

1.9B

Volume

627K

High

75.21

P/E Ratio

-22.67

52-wk high

89.11

Low

66.00

Div yield

N/A

52-wk low

1.29

GeneDx shares rose after the company reported better-than-expected Q3 financial results and increased its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 1:29 pm

GeneDx has raised its 2024 revenue guidance to $284M-$290M, up from $255M-$265M, surpassing the consensus of $263.37M. The company also expects to improve its adjusted gross margin to at least 62% and reduce net cash usage to $60M-$65M.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:04 pm

GeneDx Holdings (NASDAQ:WGS) reported better-than-expected Q3 2024 results with a GAAP EPS of $(0.31), beating the estimate of $(0.50), and sales of $76.87M, surpassing the $64.99M estimate. Sales increased by 44.22% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:02 pm

Craig-Hallum analyst Bill Bonello has maintained a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raised the price target from $46 to $70.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 5:59 pm

GeneDx Holdings (NASDAQ:WGS) has received mixed analyst ratings, with a recent increase in average price targets. Analysts have raised their price targets, reflecting a more optimistic outlook. The company has shown strong revenue growth but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 5:01 pm

Goldman Sachs analyst Matthew Sykes maintains a Neutral rating on GeneDx Holdings (NASDAQ:WGS) but raises the price target from $32 to $54.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 1:37 pm

GeneDx (NASDAQ:WGS) has provided genomic newborn screenings for over 14,000 infants, positioning itself as a leader in genomic newborn screening (gNBS). Their research shows that early diagnosis through gNBS can significantly reduce time-to-diagnosis, potentially improving health outcomes.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 12:46 pm

Wells Fargo has initiated coverage on GeneDx Holdings with an Equal-Weight rating and set a price target of $34.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 9:50 pm

TD Cowen analyst Dan Brennan maintains a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $46 to $50.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 7:04 pm

BTIG analyst Mark Massaro maintains a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $35 to $45.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 6:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.